15-Feb-2011 - Molzym GmbH & Co. KG

Researchers identify non-culturable microbes from bloodstream infections

Molzym has developed in collaboration with NorDiag ASA the first automated platform worldwide for the culture-independent universal identification of microorganisms from whole blood. Clinical studies have shown that a high proportion of microbial infections are not detectable by conventional growth culture. Microbial growth in culture media can be inhibited by antibiotic pretreatment and complex microbial nutrition requirements. A group of researchers from the Institute of Medical Microbiology, Ulm, Germany recently have shown in a study on culture-independent broad-range identification of microbes from bloodstream, synovial fluid and CSF infections that up to 63% of infections are culture negative. Conventional culturing of bacterial and fungal infections can take up to seven days for identification of the organism.

Nosocomial infections and antibiotic resistances have dramatically increased in recent years, and there is increased demand in the hospitals for rapid, sensitive, culture-independent identification technologies.

Generally, molecular identification can help filling the dangerous gap of culture-negative infections (CNI). Because infections are caused by a broad-range of pathogens, molecular technologies that enable the verification of any microbial strain from clinical specimens are demanded.

Facts, background information, dossiers
More about Molzym
More about NorDiag
  • News

    Cooperation between NorDiag and Molzym

    NorDiag and Molzym have now succeeded to combine their respective technologies into an integrated system for automated molecular detection of pathogens, among others for sepsis testing. Following this milestone, the two companies have signed a firm collaboration agreement regarding sale of ... more

    NorDiag enters distribution and collaboration agreement with Molzym

    NorDiag has entered into two distribution agreements with German based Molzym GmbH & Co KG covering Molzym’s molecular diagnostic products. The first agreement is geographically restrained to USA and Canada, while the second agreement covers the Nordic countries. NorDiag has also entered i ... more

    GE Healthcare grants license for biomagnetic isolation of nucleic acids to NorDiag ASA

    GE Healthcare, a unit of General Elecrtic, announced that it has completed a license agreement with NorDiag ASA, granting NorDiag ASA access to GE Healthcare patents for the biomagnetic isolation of nucleic acids. The license, which is valid for the lifetime of the patents, grants NorDiag A ... more

  • Companies

    NorDiag ASA

    NorDiag is a biotechnology company with focus on genebased diagnostics in the fields of cancer and infectious diseases for human disease. The Company's first product in cancer detection is Genefec™ for the early diagnosis of colorectal cancer. The company has other applications for diagnosi ... more